Kris Vaddi, PhD


Kris Vaddi, PhD

Kris Vaddi, Ph.D. is a drug discovery scientist and the founder of cancer focused startup companies Orsenix and Prelude Therapeutics, and a not-for-profit venture Sidus Healthcare.

Prior to his new ventures, Kris had a 14-year career at Incyte starting as a founding scientist and an executive director in 2002 and most recently as a group vice president in 2016. Kris initiated and championed JAK research programs at Incyte that led to the discovery, development and approval of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia Vera and Olumiant® (Baricitinib) for rheumatoid arthritis. Kris received his Doctorate in Veterinary Medicine from APAU in India and his Ph.D. from University of Florida.

Take the steps you need to help change your prognosis.



Get free, timely information on living with an MPN.